IRVINE, Calif., Dec. 1, 2005 (PRIMEZONE) -- "Recent announcements by biotechnology firms related to the development of new treatments and cures for cancer have stoked interest in biotechnology," stated SmallCap Sentinel analyst, D.R. Clark. "Few things resonate more with the investing public than technology that addresses one of our true mortal fears in cancer. The problem- for investors- has always been in discerning which companies truly have something special in development."
"A first step in separating biotech wheat from chaff is patent approval," Clark added. "Most start-ups will never get that far though their early press releases and headlines will sing the likelihood of some future cure-all.," Clark added. "Getting to the patent stage is an entirely different and often unattainable benchmark."
"For example, Callisto Pharmaceutical's (AMEX:KAL) announcement that the U.S. Patent and Trademark Office has given a Notice of Allowance on a patent for a drug compound created by their scientists to treat and prevent a variety of inflammatory diseases of the bowel such as colon cancer signals a real milestone for that company," Clark added. "This doesn't happen everyday, let alone for mid-size firms like Callisto."
Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at:
The report will address issues regarding emergent biotechnology potentially affecting drug makers such as Medimmune Inc. (NasdaqNM:MEDI), Genentech Inc. (NYSE:DNA), Novartis AG (NYSE:NVS).
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link:
http://www.trilogy-capital.com/kal_summary.aspx
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.